LTFS
MRNS

Ladenburg Thalmann Financial Services’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,000
Closed -$17K – 5452
2019
Q1 		$17K Buy
1,000
+250
+33% +$3.6K ﹤0.01% 4116
2018
Q4 		$9K Sell
750
-999
-57% -$20.2K ﹤0.01% 4358
2018
Q3 		$70K Buy
+1,749
New +$49.8K ﹤0.01% 3103

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Ladenburg Thalmann Financial Services's MRNS Position: Q2 2019 in Review

Ladenburg Thalmann Financial Services sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2019, closing a stake of 1,000 shares — an estimated $17K sold.

Ladenburg Thalmann Financial Services first reported a position in MRNS in Q3 2018 and held it in 3 quarters. The position peaked at $70K in Q3 2018. 77 funds tracked by Wall St. Rank hold MRNS as of Q2 2019.

  • Ladenburg Thalmann Financial Services reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2019 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 1,000 Marinus Pharmaceuticals, Inc shares in Q2 2019, an estimated $17K.
  • Ladenburg Thalmann Financial Services first reported a position in Marinus Pharmaceuticals, Inc in Q3 2018 and held it in 3 quarters.
  • Ladenburg Thalmann Financial Services's Marinus Pharmaceuticals, Inc position peaked at $70K in Q3 2018.
  • 77 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q2 2019, filed 15 Aug 2019.